| [1] |
Siegel R, Naishadham D, Jemal A. Cancer statistics[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
|
| [2] |
van Meurs HS, Tajik P, Hof MH, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage ⅢC or Ⅳ ovarian cancer? An exploratory analysis of the European Organization for Research and Treatment of Cancer 55971 randomised trial[J]. Eur J Cancer, 2013, 49(15): 3191-201.
|
| [3] |
Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer[J]. Ann Surg Oncol, 2012, 19(13): 4059-67.
|
| [4] |
Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced stage ovarian cancer: redefining 'optimal' residual disease[J]. Gynecol Oncol, 2012, 125(2): 483-92.
|
| [5] |
Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma[J]. Gynecol Oncol, 2013, 129(1): 63-8.
|
| [6] |
Dewdney SB, Rimel BJ, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists[J]. Gynecol Oncol, 2010, 119(1): 18-21.
|
| [7] |
Keyver-Paik MD, Zivanovic O, Rudlowski C, et al. Interval debulking surgery in patients with Federation of Gynecology and Obstetrics(FIGO) stage ⅢC and Ⅳovarian cancer[J]. Onkologie, 20 13, 36(6): 324-32.
|
| [8] |
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage ⅢC or Ⅳovarian cancer[J]. N Engl J Med, 2010, 363(10): 943-53.
|
| [9] |
Rauh-Hain JA, Rodriguez N, Growdon WB, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage Ⅳ ovarian cancer[J]. Ann Surg Oncol, 2012, 19(3): 959-65.
|
| [10] |
Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs. neoadjuvant chemotherapy( NACT)[J]. Gynecol Oncol, 2012, 12 4(1): 10-4.
|
| [11] |
Le T, Faught W, Hopkins L, et al. Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?[J]. J Obstet Gynaecol Can, 2009, 31(1): 42-7.
|
| [12] |
Milam MR, Tao X, Coleman RL, et al. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer[J]. Int J Gynecol Cancer, 2011, 21(1): 66-71.
|
| [13] |
Fagö-Olsen CL, Ottesen B, Kehlet H, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study[J]. Gynecol Oncol, 2014, 13 2(2): 292-8.
|
| [14] |
Muraji M, Sudo T, Iwasak, et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surger[J]. Gynecol Oncol, 2013, 131(3): 531-4.
|
| [15] |
Kehoe S, Hook J, Nankivell M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC-CHORUS trial[J]. J Clin Oncol, 2013, 31(Suppl): abstr 5500.
|
| [16] |
Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy[J]. Ther Adv Med Oncol, 2014, 6(6): 293-304.
|
| [17] |
Rauh-Hain JA, Rodriguez N, Growdon WB, et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage Ⅳ ovarian cancer[J]. Ann Surg Oncol, 2012, 19(3): 959-65.
|
| [18] |
Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with FIGO stage ⅢC to stage Ⅳovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective french multicentric study[J]. Int J Gynecol Cancer, 2012, 22(8): 1337-43.
|
| [19] |
Fagö-Olsen CL, Håkansson F, Antonsen SL, et al. Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients[J]. Acta Obstet Gynecol Scand, 2013, 92(6): 721-6.
|
| [20] |
Hynninen J, Lavonius M, Oksa S, et al. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?[J]. Gynecol Oncol, 2013, 128(2): 229-32.
|
| [21] |
Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction[J]. Gynecol Oncol, 2007, 104 (2): 480-90.
|
| [22] |
Vanessa CM, Ângelo BS, Carlos HA, et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness[J]. Gynecol Oncol, 2014, 132(2): 287-91.
|
| [23] |
Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer-molecular characteristics and clinical implications[J]. Gynecol Oncol, 2014, 132(2): 506-12.
|
| [24] |
Zhang GN, Liu H, Huang JM, et al.TP53 K351N mutationassociated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer[J]. Gynecol Oncol, 2014, 13 2(3): 752-7.
|
| [25] |
Matsuo K, Eno ML, Im DD, et al. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas[J]. Arch Gynecol Obstet, 20 10, 281(2): 325-8.
|
| [26] |
Segev Y, Gemer O, Auslender R, et al. Advanced ovarian cancer: primary debulking(PDS) or neoadjuvant chemotherapy(NACT)- still a debate[J]. Harefuah, 2014, 153(9): 527-31, 558.
|
下载:
